GlassScriptPhysician profile
Alice Miller
NPI 1528244555
$2,882.67
in general payments reported to CMS, 2019-2025
32 companies · $664 in 2025
The $664 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $106 · 2021: $326 · 2022: $301 · 2023: $565 · 2024: $767 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,995.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $618.60 | 2021-2025 | |
| Glaxosmithkline, LLC. | $301.68 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $279.00 | 2021-2025 | |
| Novo Nordisk INC | $221.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $205.28 | 2019-2025 | Veozah |
| Lilly USA, LLC | $146.81 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.92 | 2021-2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.25 | 2022-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $96.11 | 2019-2024 | Otezla, Repatha |
| Exact Sciences Corporation | $85.83 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $67.60 | 2020-2025 | Gardasil 9, Capvaxive, Lagevrio |
| Otsuka America Pharmaceutical, INC. | $65.40 | 2023-2024 | Rexulti |
| Seqirus USA INC | $56.89 | 2023-2024 | Fluad Quadrivalent, Flucelvax Quadrivalent, Fluad |
| Incyte Corporation | $53.35 | 2023-2024 | Opzelura |
| Collegium Pharmaceutical, INC. | $45.61 | 2022-2024 | Belbuca |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $43.93 | 2024-2025 | Airsupra |
| Insulet Corporation | $42.69 | 2024-2025 | Omnipod |
| Janssen Pharmaceuticals, INC | $37.63 | 2019-2022 | |
| Kyowa Kirin, INC. | $26.29 | 2024 | Crysvita |
| Amarin Pharma, INC. | $26.27 | 2020-2021 | |
| Mylan Specialty L.P. | $25.71 | 2022-2024 | Yupelri |
| Axsome Therapeutics, INC. | $25.41 | 2025 | Auvelity |
| Upsher-Smith Laboratories LLC | $25.31 | 2021 | |
| Abbott Laboratories | $23.24 | 2023 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $21.99 | 2024 | Gemtesa |
| Allergan, INC. | $20.03 | 2020 | |
| Mannkind Corporation | $19.42 | 2022 | |
| Genentech USA, INC. | $18.97 | 2019 | |
| Amneal Pharmaceuticals LLC | $18.69 | 2025 | Unithroid |
| Sanofi Pasteur INC. | $16.73 | 2023 | |
| Bausch Health US, LLC | $16.18 | 2021 | |
| Fidia Pharma USA INC. | $15.17 | 2025 | Hymovis, Triluron |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.